International Journal of Neuropsychopharmacology
September 9, 2026
T Solomon, R Barrow, D Karlin et al.
Abstract Background Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed. Aims & Objectives To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD. Method This phase 2b, multicenter, randomized, double-blind, placebo-controlled study...
JAMA
October 21, 2025
Reid Robison, Robert Barrow, Craig Conant et al.
22 citations
Effective and well-tolerated pharmacotherapies for generalized anxiety disorder (GAD), which is one of the most common psychiatric disorders, are needed. To determine the dose-response relationship of MM120 (lysergide D-tartrate) in adults with moderate to severe GAD. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study enrolled 198 adults aged 18 to 74 years with a...
Current opinion in obstetrics & gynecology
February 1, 2025
Teresa Khoo, Daniel R Karlin, Christopher Pietras
This review assesses the impact of early integration of palliative care and the disparities that exist among patients with gynecologic malignancies. It also highlights the recent advances in symptom management, goals of care communication, and end of life care. Although palliative care has been utilized earlier, there are still barriers to its integration both nationally and worldwide,...
Frontiers in digital health
2023
Todd M Solomon, Matus Hajduk, Martin Majernik et al.
1 citation
Spravato and other drugs with consciousness-altering effects show significant promise for treating various mental health disorders. However, the effects of these treatments necessitate a substantial degree of patient monitoring which can be burdensome to healthcare providers and may make these treatments less accessible for prospective patients. Continuous passive monitoring via digital devices...